Cargando…

Role of PCIF1‐mediated 5′‐cap N6‐methyladeonsine mRNA methylation in colorectal cancer and anti‐PD‐1 immunotherapy

Adenosine N6‐methylation (m6A) and N6,2′‐O‐dimethylation (m6Am) are regulatory modifications of eukaryotic mRNAs. m6Am formation is catalyzed by the methyl transferase phosphorylated CTD‐interacting factor 1 (PCIF1); however, the pathophysiological functions of this RNA modification and PCIF1 in can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lingling, Wu, Lujing, Zhu, Zhouting, Zhang, Qiong, Li, Wanyu, Gonzalez, Gwendolyn Michelle, Wang, Yinsheng, Rana, Tariq M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841328/ https://www.ncbi.nlm.nih.gov/pubmed/36514940 http://dx.doi.org/10.15252/embj.2022111673

Ejemplares similares

PCIF1-mediated deposition of 5′-cap N(6),2′-O-dimethyladenosine in ACE2 and TMPRSS2 mRNA regulates susceptibility to SARS-CoV-2 infection
por: Wang, Lingling, et al.
Publicado: (2023)

HIV reprograms host m(6)Am RNA methylome by viral Vpr protein-mediated degradation of PCIF1
por: Zhang, Qiong, et al.
Publicado: (2021)

Enzymatic characterization of mRNA cap adenosine-N6 methyltransferase PCIF1 activity on uncapped RNAs
por: Yu, Dan, et al.
Publicado: (2022)

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
por: Zhu, Zhouting, et al.
Publicado: (2023)

PCIF1, the only methyltransferase of N6,2-O-dimethyladenosine
por: Wu, Yuting, et al.
Publicado: (2023)

Enzymatic Characterization of In Vitro Activity of RNA Methyltransferase PCIF1 on DNA
por: Yu, Dan, et al.
Publicado: (2022)

The CTBP2-PCIF1 complex regulates m(6)Am modification of mRNA in head and neck squamous cell carcinoma
por: Li, Kang, et al.
Publicado: (2023)

m(6)Am methyltransferase PCIF1 is essential for aggressiveness of gastric cancer cells by inhibiting TM9SF1 mRNA translation
por: Zhuo, Wei, et al.
Publicado: (2022)

A Pan-Cancer Analysis of the Oncogenic and Immunogenic Role of m6Am Methyltransferase PCIF1
por: Jin, Ming-Zhu, et al.
Publicado: (2021)

ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment
por: Li, Na, et al.
Publicado: (2020)

Assessment of PD-L1 mRNA expression in gastrointestinal tumors and the response to immunotherapy
por: Qiu, Qingqing, et al.
Publicado: (2022)

Regulation of mRNA cap methylation
por: Cowling, Victoria H.
Publicado: (2009)

m(6)A-RNA Demethylase FTO Inhibitors Impair Self-Renewal in Glioblastoma Stem Cells
por: Huff, Sarah, et al.
Publicado: (2021)

Arabidopsis DXO1 activates RNMT1 to methylate the mRNA guanosine cap
por: Xiao, Chen, et al.
Publicado: (2023)

Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains
por: Zhang, Qiong, et al.
Publicado: (2022)

mRNA Cap-1 Methyltransferase in the SARS Genome
por: von Grotthuss, Marcin, et al.
Publicado: (2003)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

RAM/Fam103a1 Is Required for mRNA Cap Methylation
por: Gonatopoulos-Pournatzis, Thomas, et al.
Publicado: (2011)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

mRNA Cap Methylation in Pluripotency and Differentiation
por: Grasso, Laura, et al.
Publicado: (2016)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Exosomal PD-L1: an effective liquid biopsy target to predict immunotherapy response
por: Song, Yanling, et al.
Publicado: (2019)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
por: Sun, Chengliang, et al.
Publicado: (2022)

Synthetic mRNA capping
por: Muttach, Fabian, et al.
Publicado: (2017)

Myc and mRNA capping()
por: Dunn, Sianadh, et al.
Publicado: (2015)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

The role of exosomal PD-L1 in tumor immunotherapy
por: Wang, Jing, et al.
Publicado: (2021)

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
por: Cai, Jiajing, et al.
Publicado: (2019)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
por: Jiang, Wenxiao, et al.
Publicado: (2021)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

m(6)A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy
por: Wang, Lingling, et al.
Publicado: (2020)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fq3pve5lintavft4imuu592n6a